Meeting
2022 ASCO Annual Meeting
Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma.
Authors
Gregory P. Botta
UCSD Moores Cancer Center, La Jolla, CA
Gregory P. Botta , Carlos Roberto Becerra , Zhaohui Jin , Dae Won Kim , Dan Zhao , Heinz-Josef Lenz , Hong Ma , Audrey Ween , Petra Acha , Zonghai Li , Harry H. Yoon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04404595
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2538)
DOI
10.1200/JCO.2022.40.16_suppl.2538
Abstract #
2538
Poster Bd #
193
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial.
First Author: Gregory P. Botta
Poster
2024 ASCO Annual Meeting
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
First Author: Armin Ghobadi
Poster
2023 ASCO Annual Meeting
Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.
First Author: Navin R. Pinto
Poster
2022 ASCO Annual Meeting
Decreasing HPK1 expression in CD19 CAR-T cells: A novel strategy to overcome challenges of cell therapy for adult (r/r) B-ALL.
First Author: Na Zhang